Post-marketing clinical safety evaluation of Shexiang Tongxin dropping pill and centralized monitoring in hospitals

Status

Active, not recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2300070706

Enrollment

Unknown

Registered

2023-04-20

Start date

2023-04-14

Completion date

Unknown

Last updated

2023-06-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Circulation system, cardiology, non communicable diseases

Interventions

Experimental group:There are no restrictions on this study.

Eligibility

Sex/Gender

All

Age

1 Years to 100 Years

Inclusion criteria

Inclusion criteria: 1. According to the indications in the instructions of Shexiang Tongxin Dropping Pills, or according to the patient's condition, the clinical physician determines that it is suitable for patients to apply Shexiang Tongxin Dropping Pills. 2. Patients who voluntarily participate and agree to sign an informed consent form.

Exclusion criteria

Exclusion criteria: 1. Individuals with a known history of allergies to Shexiang Tongxin Dropping Pills. 2. Researchers determine that they cannot complete or are not suitable to participate in this study.

Design outcomes

Primary

Measure	Time frame
Adverse Drug Reaction;	—

Countries

China

Contacts

Public ContactHu YuanHui

Guanganmen Hospital, China Academy of Chinese Medical Sciences

huiyuhui55@sohu.com+86 13911386285

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026